Cadila Healthcare’s subsidiary, has received approval from the US health regulator for Clozapine tablets, which is used to treat schizophrenia.

In a filing the company stated, “Zydus Pharmaceuticals USA Inc, a wholly owned subsidiary of Cadila Healthcare, has received the final approval from the US Food and Drug Administration to market Clozapine tablets in strengths of 25 mg, 50 mg, 100 mg and 200 mg.”

Further, the tablets will be manufactured at group’s formulations manufacturing facility at SEZ, Ahmedabad.

Read EquityPandit’s Technical Analysis on Nifty Pharma Outlook for the Week